Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
Avalo Therapeutics expanded its pipeline with AVTX-010, a long-acting next-generation anti-IL-1β antibody targeting immune-mediated inflammatory diseases like hidradenitis suppurativa. The company plans to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027, leveraging positive Phase 2 data from its lead asset abdakibart.
Key figures
- Ind submission timing
- first half of 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.